The future of precision medicine

By pairing companion imaging agents with small molecule drug conjugates (SMDCs), Endocyte can provide a more accurate picture of a patient’s disease status—and treatment prognosis.  Learn more

Endocyte strives for precision in medicine

Our treatment philosophy is based on precision—targeting the right patient, the right disease, and the right cells.  Learn more

ENDOCYTE TECHNOLOGY

Our SMDCs are designed to precisely deliver potent compounds with selective activation. Each corresponding companion imaging agent can be viewed with nuclear imaging equipment to assist in therapy selection. 

Watch our technology at work

CLINICAL TRIALS

Several of our SMDCs and companion imaging agents are currently in clinical trials for treatment of:

  • Ovarian cancer
  • Non-small cell lung cancer
  • Advanced solid tumors

Learn more

* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

ENDOCYTE PIPELINE

Potential treatments for advanced solid tumors and ovarian and lung cancers are in late-stage trials and under review for conditional approval in Europe. In addition, three new SMDCs are currently entering clinical trials.*
Our pipeline

Current Pipeline

EC145 Vintafolide (Cancer)*
EC1456 (Folate-Tubulysin) Cancer*
EC0652 (Prostate Cancer)*
EC20 Etarfolatide (Molecular Imaging)*

Discovery Stage Agents

Endocyte currently has in early stage preclinical development a prostate-specific membrane antigen (PSMA) targeted drug, a therapeutic for inflammatory diseases, and a therapeutic for the treatment of polycystic kidney disease.*
Learn more